OncoMatch/Clinical Trials/NCT06934057
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Is NCT06934057 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Nivolumab and Cabozantinib for kidney cancer.
Treatment: Nivolumab · Cabozantinib — The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
No prior treatment (treatment-naive required)
Max 0 prior lines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify